MedPath

Evofem Biosciences, Inc.

Evofem Biosciences, Inc. logo
🇺🇸United States
Ownership
Public
Established
2009-01-01
Employees
51
Market Cap
$1M
Website
http://www.evofem.com

Clinical Trials

7

Active:0
Completed:6

Trial Phases

3 Phases

Phase 1:1
Phase 2:1
Phase 3:5

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (7 trials with phase data)• Click on a phase to view related trials

Phase 3
5 (71.4%)
Phase 1
1 (14.3%)
Phase 2
1 (14.3%)

Evaluation of EVO100 for Prevention of Urogenital Chlamydia Trachomatis and Neisseria Gonorrhoeae Infection

Phase 3
Completed
Conditions
Sexually Transmitted Diseases
Gonorrhea
Chlamydia
Interventions
Drug: Placebo
First Posted Date
2020-09-17
Last Posted Date
2024-01-30
Lead Sponsor
Evofem Inc.
Target Recruit Count
1892
Registration Number
NCT04553068
Locations
🇺🇸

Cahaba Medical Care, Birmingham, Alabama, United States

🇺🇸

Mobile Obstetrics & Gynecology, P.C., Mobile, Alabama, United States

🇺🇸

Marchand OBGYN, Mesa, Arizona, United States

and more 88 locations

AMP002 Phase III Contraceptive Study

Phase 3
Completed
Conditions
Contraception
Interventions
First Posted Date
2017-08-09
Last Posted Date
2020-09-17
Lead Sponsor
Evofem Inc.
Target Recruit Count
1384
Registration Number
NCT03243305
Locations
🇺🇸

Coastal Clinical Research, Inc., Mobile, Alabama, United States

🇺🇸

East Valley Family Physicians 137, Chandler, Arizona, United States

🇺🇸

Mesa Obstetricians & Gynecologists 184, Mesa, Arizona, United States

and more 84 locations

Phase 2B/3 Double-blinded Placebo-controlled

Phase 2
Completed
Conditions
Chlamydia Trachomatis Infection
Interventions
Drug: Placebo
First Posted Date
2017-04-11
Last Posted Date
2020-08-12
Lead Sponsor
Evofem Inc.
Target Recruit Count
860
Registration Number
NCT03107377
Locations
🇺🇸

Coastal Clinical Research, Inc., Mobile, Alabama, United States

🇺🇸

Mobile OB-GYN, PC, Mobile, Alabama, United States

🇺🇸

MedPharmics, LLC, Phoenix, Arizona, United States

and more 47 locations

Duration of Effect of Acidform Gel on Vaginal pH

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: Acidform 5 g
Drug: Acidform 4 g
Drug: Placebo 4 g
Drug: Acidform 3 g
First Posted Date
2016-02-26
Last Posted Date
2020-11-20
Lead Sponsor
Evofem Inc.
Target Recruit Count
105
Registration Number
NCT02693418
Locations
🇺🇸

Johns Hopkins Bayview Medical Center, Baltimore, Maryland, United States

🇺🇸

Metro Health Medical Center, Cleveland, Ohio, United States

Extension Study to Evaluate the Post-Treatment Safety and Duration of Clinical Effect of LIPO-202

Phase 3
Terminated
Conditions
Central Abdominal Bulging
Interventions
Drug: Placebo
First Posted Date
2015-06-29
Last Posted Date
2019-12-10
Lead Sponsor
Evofem Inc.
Target Recruit Count
100
Registration Number
NCT02483533
  • Prev
  • 1
  • 2
  • Next

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.